Last updated: July 23, 2026
SUPERNUS v. TWI Pharmaceuticals (1:15-cv-00369): Litigation Summary, Patent-Scope Analysis, and Generic-Entry Risk
Executive summary: The case SUPERNUS PHARMACEUTICALS, INC. v. TWI PHARMACEUTICALS, INC. (1:15-cv-00369) is a Hatch-Waxman-style intellectual property dispute tied to ANDA-based generic development. The record indicates the litigation centered on one or more Orange Book-listed patents associated with a Supernus-branded product and TWI’s proposed generic, with the key business implication being whether TWI could obtain FDA approval and launch without infringing the asserted patent claims.
However, a complete, accurate litigation summary and claim-level patent-scope analysis cannot be produced from the provided input alone. The case docket number is given, but no complaint/answer/judgment, asserted patent identifiers, Orange Book reference drug, claim construction orders, infringement/invalidity rulings, settlement terms, or outcome dates are included.
What patents were asserted in SUPERNUS PHARMACEUTICALS v. TWI PHARMACEUTICALS (1:15-cv-00369)?
Featured snippet answer: Not determinable from the provided information.
Which Orange Book patents typically get asserted in Supernus TWI disputes?
When Supernus sues under Hatch-Waxman, the asserted set commonly includes:
- Drug substance composition patents (active ingredient or analogs)
- Drug product formulation patents (excipients, release control systems)
- Method-of-use patents (patient selection or dosing method)
- Manufacturing/process patents (granulation, coating, particle engineering)
But the actual asserted patent list for 1:15-cv-00369 is not provided, so the patent estate cannot be enumerated.
How did the court rule on infringement and invalidity in 1:15-cv-00369?
Featured snippet answer: Not determinable from the provided information.
What outcomes matter for launch timing?
For generic-entry risk modeling, the critical case milestones are:
- Final judgment on infringement
- Final judgment on invalidity
- Determinations on indefiniteness, obviousness, written description, enablement, and anticipation
- Any claim construction affecting infringement scope
- Any injunction duration or stay tied to the settlement posture
None of these disposition details are included in the prompt.
When does 1:15-cv-00369 settlement or court outcome affect generic launch?
Featured snippet answer: Not determinable from the provided information.
What typically drives exclusivity vs patent-driven launch barriers
In Hatch-Waxman cases, launch is blocked by:
- Patent expiration (earliest non-infringement patent date)
- Staggered expiry across multiple Orange Book patents
- Five-year new chemical entity exclusivity or three-year exclusivity (if applicable)
- 30-month stay effects, if a Paragraph IV notice triggered litigation
- Settlement-triggered “carve-outs” (design-around product specs, launch date commitments)
No Paragraph IV notice date, Orange Book expiry dates, or settlement terms are supplied, so no timeline can be computed.
Was this a Paragraph IV challenge, and what was the Paragraph IV notice date?
Featured snippet answer: Not determinable from the provided information.
Paragraph IV elements needed for a risk assessment
A proper litigation-to-FDA mapping usually requires:
- The FDA ANDA submission and reference listed drug (RLD)
- The Paragraph IV certification(s) against specific listed patents
- The notice date (statutory timing and 30-month stay calculation)
- Whether the case included multiple patents and multiple certifications
These inputs are missing, so a Paragraph IV characterization cannot be stated.
What is the strongest part of SUPERNUS’s patent case in this dispute?
Featured snippet answer: Not determinable from the provided information.
How to evaluate “strongest” patents in practice
In litigation analytics, strongest patents are typically those with:
- Close factual match to the proposed generic product attributes
- Clear, narrow claim scope that survives invalidity
- Prior PTAB or Federal Circuit stability (if applicable)
- Clean prosecution history that limits estoppel
But without the asserted patents and rulings, no strength ranking is possible.
Which claims and product elements did TWI challenge as non-infringing or invalid?
Featured snippet answer: Not determinable from the provided information.
Claim elements that usually become the battleground
Depending on the patent type, infringement disputes often hinge on:
- Drug release profile and formulation parameters
- Specific chemical structures or substituent patterns
- Treatment regimen claims (dosage, titration, timing)
- Manufacturing constraints that map to product specs
No claim language or technology description is provided, so the dispute cannot be mapped.
What does this case imply about biosimilar or non-biosimilar generic risk?
Featured snippet answer: Not determinable from the provided information.
Why this matters
- If the product is small molecule, Hatch-Waxman and Paragraph IV rules govern generic entry.
- If the product is biologic, the framework is BPCIA and biosimilar exclusivity differs.
The therapeutic and modality for the litigated product are not provided, so biosimilar risk cannot be addressed.
How does SUPERNUS v. TWI compare with other Supernus patent litigations?
Featured snippet answer: Not determinable from the provided information.
What a comparative analysis would require
To compare litigation patterns across cases, you need:
- Repeated asserted patent families
- Claim construction outcomes and appeal posture
- Settlement norms (early resolution vs late-stage trial)
- Consistency of invalidity theories
No asserted families or outcomes are included, so comparison is not possible.
What is the current status of 1:15-cv-00369 (dismissed, settled, trial, judgment, appeal)?
Featured snippet answer: Not determinable from the provided information.
Status items that drive licensing and investment decisions
- Whether the case ended in final judgment or stipulated dismissal
- Whether the patents were held invalid or not infringed
- Whether there is a Federal Circuit appeal
- Whether there is an enforceable settlement agreement
- Whether the district court issued an injunction or entered stipulated launch dates
These docket outcomes are not provided.
Key data table: what is missing to complete an accurate litigation summary
| Litigation field needed |
Required source in docket/filings |
Provided in prompt |
| Case outcome (dismissal/judgment/settlement) |
Docket + final order |
No |
| Court (district, judge) |
Caption/order |
No |
| Asserted patent numbers |
Complaint/Amended complaint |
No |
| RLD and Orange Book patents |
FDA listing + asserted-patent mapping |
No |
| Paragraph IV certification(s) |
ANDA notice + complaint allegations |
No |
| Claim construction order dates |
Markman order |
No |
| Trial/bench disposition or summary judgment |
Opinion(s) |
No |
| Injunction / stayed claims |
Injunction order |
No |
| Settlement effective dates and launch carve-outs |
Settlement agreement/consent judgment |
No |
| Appeal status |
Notice of appeal entries |
No |
Key Takeaways
- The case number (1:15-cv-00369) identifies the litigation, but the asserted patents, procedural posture, and disposition are not provided.
- Without the complaint/claim list and outcome orders, no reliable patent-scope analysis or generic launch risk timeline can be produced.
FAQs
- What patents are listed in the Orange Book for the Supernus RLD involved in 1:15-cv-00369?
- Did SUPERNUS assert composition, formulation, or method-of-use patents against TWI in case 1:15-cv-00369?
- What did the court construe regarding disputed claim terms in SUPERNUS v. TWI (1:15-cv-00369)?
- Was there a 30-month stay triggered, and when did it expire for TWI’s ANDA in 1:15-cv-00369?
- Did the parties enter a settlement that set a specific launch date or product-design carve-outs in 1:15-cv-00369?
References
- Provided prompt only: “SUPERNUS PHARMACEUTICALS, INC. v. TWI PHARMACEUTICALS, INC. | 1:15-cv-00369.”
